Who is sponsoring NCT04801563?

NCT04801563 is sponsored by University Of Perugia.

What drugs are being tested in NCT04801563?

Interventions in NCT04801563: MDS and AlloHSCT.

What condition does NCT04801563 study?

NCT04801563 studies MDS and Allogeneic Stem Cell Transplantation.

Is NCT04801563 still recruiting?

NCT04801563 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04801563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS

Status unknown NA Last updated 17 March 2021

What this trial tests

NA trial testing MDS and AlloHSCT in MDS and Allogeneic Stem Cell Transplantation in 80 participants. Status unknown.

Timeline

20 September 2019

Primary endpoint
19 September 2025

19 September 2025

Quick facts

Lead sponsor	University Of Perugia
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	20 September 2019
Primary completion	19 September 2025
Estimated completion	19 September 2025
Sites	1 location across Italy

Drugs / interventions tested

MDS and AlloHSCT

Conditions studied

MDS and Allogeneic Stem Cell Transplantation — all drugs for MDS and Allogeneic Stem Cell Transplantation →

Sponsor

University Of Perugia

Who can join

Under 70, any sex, with MDS and Allogeneic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An "intention-to-treat" study to evaluate the impact of allogeneic HSCT with Total Marrow and Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Of Perugia trials

Trials by the same sponsor.

NCT05912894 — Anatomical Variation in Rouvière's Sulcus · not yet recruiting
NCT06544343 — Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy · NA · recruiting
NCT06398145 — D-chiro-inositol and AUB · Phase 2 · not yet recruiting
NCT07288632 — Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung C · recruiting
NCT06246604 — Screening for Deep Vein Thrombosis in Intensive Care · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801563 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Of Perugia
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing